Catheter Precision Files S-1 for Potential Securities Offering

TL;DR

Catheter Precision (formerly Ra Medical) filed an S-1, looks like they're prepping to sell stock.

AI Summary

Catheter Precision, Inc. filed an S-1 registration statement on June 3, 2024, to register an unspecified number of securities. The company, formerly known as Ra Medical Systems, Inc., is incorporated in Delaware and headquartered in Fort Mill, SC. David Jenkins serves as the Executive Chairman and CEO. The filing indicates a potential offering of securities, but specific details on the amount or terms are not yet disclosed.

Why It Matters

This S-1 filing signals Catheter Precision, Inc.'s intention to raise capital through the sale of securities, which could impact its financial structure and future growth strategies.

Risk Assessment

Risk Level: medium — S-1 filings often precede stock offerings, which carry inherent market and execution risks for the company and investors.

Key Numbers

• 333-279930 — SEC File Number (Identifies this specific registration statement)
• 3841 — SIC Code (Industry classification for Surgical & Medical Instruments & Apparatus)

Key Players & Entities

• Catheter Precision, Inc. (company) — Registrant
• Ra Medical Systems, Inc. (company) — Former company name
• June 3, 2024 (date) — Filing date
• David Jenkins (person) — Executive Chairman and CEO
• Delaware (jurisdiction) — State of incorporation
• Fort Mill, SC (location) — Principal executive offices

FAQ

Key Financial Figures

• $0.0001 — common stock (the "Shares" ), par value $0.0001 per share, of Catheter Precision, Inc.,
• $0 — n stock is sold in this offering, minus $0.0001, and each Pre-Funded Warrant will
• $15.1 billion — Scientific Corp. and is estimated to be $15.1 billion by 2028 (CAGR of 13.0%). Population gro
• $3.5 billion — atheter ablation market was larger than $3.5 billion in 2022 and is estimated to grow to $14
• $14.5 billion — ion in 2022 and is estimated to grow to $14.5 billion by 2032 (13.5% CAGR). The exact numbe
• $20,000 — on at an estimated cost in the range of $20,000 or more per procedure. Specific reason

Filing Documents

• rmed_s1.htm (S-1) — 633KB
• rmed_ex10282.htm (EX-10.28) — 10KB
• rmed_ex10283.htm (EX-10.28) — 10KB
• rmed_ex10317.htm (EX-10.31) — 55KB
• rmed_ex1034.htm (EX-10.34) — 147KB
• rmed_ex231.htm (EX-23.1) — 3KB
• rmed_ex232.htm (EX-23.2) — 3KB
• rmed_ex234.htm (EX-23.4) — 3KB
• rmed_ex107.htm (EX-FILING FEES) — 39KB
• rmed_s1img9.jpg (GRAPHIC) — 4KB
• rmed_s1img17.jpg (GRAPHIC) — 4KB
• rmed_s1img16.jpg (GRAPHIC) — 23KB
• rmed_s1img15.jpg (GRAPHIC) — 7KB
• rmed_s1img14.jpg (GRAPHIC) — 35KB
• rmed_s1img13.jpg (GRAPHIC) — 5KB
• rmed_s1img12.jpg (GRAPHIC) — 8KB
• rmed_s1img10.jpg (GRAPHIC) — 3KB
• 0001654954-24-007285.txt ( ) — 1027KB

RISK FACTORS

RISK FACTORS 18 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 24 MARKET FOR COMMON STOCK DIVIDEND POLICY 25 DESCRIPTION OF PRE-FUNDED WARRANTS

USE OF PROCEEDS

USE OF PROCEEDS 26

UNDERWRITING

UNDERWRITING 31 LEGAL MATTERS 35 EXPERTS 35 WHERE YOU CAN FIND ADDITIONAL INFORMATION 35 INCORPORATION OF CERTAIN INFORMATION BY REFERENCE 36 ABOUT THIS PROSPECTUS We urge you to read carefully this prospectus, together with the information incorporated herein by reference as described under the heading " Where You Can Find Additional Information " before buying any of the securities being offered. You should rely only on the information contained or incorporated by reference in this prospectus or in any free writing prospectus. We and the underwriter have not authorized any other person to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. This prospectus may only be used where it is legal to offer and sell Shares of our common stock and other securities. If it is against the law in any jurisdiction to make an offer to sell these Shares and other securities, or to solicit an offer from someone to buy these Shares and/or other securities, then this prospectus does not apply to any person in that jurisdiction, and no offer or solicitation is made by this prospectus to any such person. You should assume that the information appearing in this prospectus or in any applicable free writing prospectus is accurate only as of the date on the front cover of this prospectus, regardless of the time of delivery of this prospectus or of any sale of common stock or other securities. Our business, financial condition, results of operations and prospects may have changed since such date. Information contained on our website is not a part of this prospectus. A prospectus supplement may add to, update or change the information contained in this prospectus. You should read both this prospectus and any applicable prospectus supplements together with additional information described below under the heading " Where You Can Find Additional Information ." This prospectus may contai

View Full Filing

View this S-1 filing on SEC EDGAR